Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
Study Details
Study Description
Brief Summary
The purpose of this study is to show that the use of low volume iso-osmolar non-ionic radio contrast medium (30 cc) in a thoracic CT Scanning procedure in a selected group of patients with chronic kidney disease (CKD) will avoid contrast induced nephropathy (CIN) in comparison to a similar group of patients with CKD who receive no contrast medium..
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
The use of radio contrast medium enhances the image quality of CT scans. However, contrast CT is avoided in patients with CKD for fear of contrast-induced nephropathy. The current standard of care for these patients is CT without contrast. Taking advantage of fast scanning capabilities of modern CT scanners (64-Multi-Detector CT), the current investigators have developed a method to use low volume iso-osmolar non-ionic radio contrast medium (30 cc) which can be used in a selected group of adult patients with mild to moderate stable CKD (eGFR 16-60 ml/min/m^2 for at least 12 months), who require thoracic CT imaging for diagnostic purposes. Up to 100 patients who meet the inclusion/exclusion criteria will be randomized to standard care (no-contrast, 50 controls) or low volume contrast CT (50 intervention group). The peak increase of serum creatinine levels within 72 hours after the CT procedure will be measured as an outcome variable for comparison between the two groups, as well as a safety monitoring variable in the intervention group (25% increase is the upper threshold).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Low Volume Contrast Subjects in this arm will receive a single intravenous injection of low volume iso-osmolar non-ionic radio contrast medium, prior to undergoing 64-MDCT scanning. The use of low volume radio contrast medium constitutes the intervention. Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan |
Drug: Low Volume iso-osmolar non-ionic radio contrast medium
Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
Other Names:
Drug: Acetylcysteine Inhalation
Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
Other Names:
Drug: Sodium Bicarbonate Solution
Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
Other Names:
Procedure: 64-MDCT Scanning
Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
Other Names:
|
| Sham Comparator: Control Subjects in this arm will undergo 64-MDCT scanning without Radio Contrast Medium (RCM). Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan |
Drug: Acetylcysteine Inhalation
Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
Other Names:
Drug: Sodium Bicarbonate Solution
Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
Other Names:
Procedure: 64-MDCT Scanning
Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Peak Serum Creatinine Level [Up to 72 hours after intervention]
The peak serum creatinine increase over baseline within 72 hours after intervention is the outcome variable. This variable is used for comparison between two groups, as well as for safety monitoring in the intervention group (25% increase is the upper threshold)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects with documented stable Chronic Kidney Disease (CKD) defined as a stable eGFR 16-60 ml/min/m^2 for ≥ 12 months; and
-
Referred to CT scanning procedure to evaluate pulmonary embolism, pulmonary malignancy, acute aortic syndromes, or renal artery stenosis.
Exclusion Criteria:
-
CKD Stages 1, 2 and 5
-
Stage 3-4 congestive heart failure (CHF)
-
Irregular supraventricular tachycardia
-
Allergic to iodinated Radio Contrast Medium (RCM)
-
Allergic to Mucomyst
-
Pregnancy
-
Evidence of acute renal failure (ARF)
-
Serum bicarbonate either less than 20 meq/L or greater than 35 meq/L
-
Hydration with a bicarbonate solution is contraindicated or considered unsafe by the subject's caring physicians
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | VA Greater Los Angeles Healthcare System | Los Angeles | California | United States | 90073 |
Sponsors and Collaborators
- VA Greater Los Angeles Healthcare System
- General Electric
Investigators
- Study Director: Dean T Yamaguchi, MD, PhD, VA Greater Los Angeles Healthcare System
Study Documents (Full-Text)
None provided.More Information
Publications
- Barack0001